Patents Assigned to Pfizer
  • Heteroaromatic compounds and their use as dopamine D1 ligands
    Patent number: 9617275
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced ?-arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: April 11, 2017
    Assignee: Pfizer Inc.
    Inventors: Jotham Wadsworth Coe, John Arthur Allen, Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Edward Raymond Guilmette, Anthony Richard Harris, Chris John Helal, Jaclyn Louise Henderson, Scot Richard Mente, Deane Milford Nason, Steven Victor O'Neil, Chakrapani Subramanyam, Wenjian Xu
  • Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
    Patent number: 9617258
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof, having the structure: or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer or diastereomer thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: April 11, 2017
    Assignee: Pfizer Inc.
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla, John I. Trujillo
  • N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides
    Patent number: 9611264
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: April 4, 2017
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Patrick Robert Verhoest, Romelia del Carmen Salomon Ferrer
  • N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL] AMIDES
    Publication number: 20170088547
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: September 22, 2016
    Publication date: March 30, 2017
    Applicant: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Patrick Robert Verhoest, Romelia del Carmen Salomon Ferrer
  • N-[2-(2-Amino-6,6-Disubstituted-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-YL)-1,3-Thiazol-4-YL]Amides
    Publication number: 20170088558
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: September 22, 2016
    Publication date: March 30, 2017
    Applicant: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Patrick Robert Verhoest, Peter Justin Mikochik, John Charles Murray, Xinjun Hou
  • N-(2-(2-AMINO-6-SUBSTITUTED-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]OXAZIN-8a(8H)-YL)-THIAZOL-4-YL) AMIDES
    Publication number: 20170088556
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2, R3, R4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: September 22, 2016
    Publication date: March 30, 2017
    Applicant: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill
  • COMBINATION OF AN ANTI-CCR4 ANTIBODY AND A 4-1BB AGONIST FOR TREATING CANCER
    Publication number: 20170088627
    Abstract: The present disclosure describes combination therapies comprising an antibody which specifically binds to human CCR4 and a selective 4-1BB agonist, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: May 15, 2015
    Publication date: March 30, 2017
    Applicants: Pfizer Inc., KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Chia-Yang Lin, Shihao Chen, LiFen Lee, Shobha Potluri, Denis Healy, Margaret Marshall, Naoki Sawada
  • 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
    Patent number: 9605007
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: March 28, 2017
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Elizabeth Mary Beck, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Gabriela Barreiro, Erik Alphie LaChapelle, Bruce Nelsen Rogers
  • Imidazopyridazine compounds
    Patent number: 9598421
    Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: March 21, 2017
    Assignee: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Patrick Robert Verhoest, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Joseph Michael Young
  • ANTI-EFNA4 ANTIBODY-DRUG CONJUGATES
    Publication number: 20170072066
    Abstract: The present invention provides for anti-EFNA4 antibody-drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: June 8, 2016
    Publication date: March 16, 2017
    Applicants: PFIZER, INC., STEMCENTRX, INC.
    Inventors: Marc Isaac DAMELIN, Kiran Manohar KHANDKE, Puja SAPRA, Alexander John BANKOVICH, Scott J. DYLLA
  • CRYSTALLINE FORM OF 6-[(4R)-4-METHYL-1,2-DIOXIDO-1,2,6-THIADIAZINAN-2-YL]ISOQUINOLINE-1-CARBONITRILE
    Publication number: 20170073338
    Abstract: This invention relates to a novel crystalline form of 6-[(4R)-4-methyl-1,1-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile which is useful as a selective androgen receptor modulator (SARM), and to compositions thereof and suitable processes for the preparation thereof.
    Type: Application
    Filed: May 1, 2015
    Publication date: March 16, 2017
    Applicant: Pfizer Inc.
    Inventors: Eugene Lvovich Piatnitski CHEKLER, Roberta Louise DOROW, Jeffrey Braden SPERRY
  • PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES
    Publication number: 20170071946
    Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A and A? are independently C or N, where C may be unsubstituted or substituted by halo or C1-C6 alkyl; R and R0 are independently selected from the group consisting of H, C1-C6 alkyl, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), and —(CH2)n—W, where W is C3-C8 cycloalkyl, phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing 1-3 N, S and/or O atoms, —SO2—R?, —NHSO2—R?, —NR?SO2—R? and SR?, where R? and R? are independently C1-C6 alkyl or C3-C8 cycloalkyl, etc.; wherein each of said alkyl, cycloalkyl, heterocyclic, phenyl, naphthyl or heteroaryl may be unsubstituted or substituted by phenyl, heteroaryl, etc.
    Type: Application
    Filed: November 3, 2016
    Publication date: March 16, 2017
    Applicant: Pfizer Inc.
    Inventors: Jotham Wadsworth Coe, Christoph Martin Dehnhardt, Peter Jones, Yogesh Anil Sabnis, Joseph Walter Strohbach, Florian Michel Wakenhut, Gavin Alistair Whitlock
  • Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors
    Publication number: 20170073343
    Abstract: The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    Type: Application
    Filed: September 12, 2016
    Publication date: March 16, 2017
    Applicant: Pfizer Inc.
    Inventors: Paul Galatsis, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Matthew Richard Reese, Antonia Friederike Stepan, Patrick Robert Verhoest, Travis T. Wager, Martin Youngjin Pettersson, Michelle Renee Garnsey
  • Axl inhibitors
    Patent number: 9593097
    Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: March 14, 2017
    Assignee: Pfizer Inc.
    Inventors: Ted William Johnson, Paul Francis Richardson, Michael Raymond Collins, Daniel Tyler Richter, Benjamin Joseph Burke, Sacha Ninkovic, Ketan Satish Gajiwala, Maria Angelica Linton, Phuong Thi Quy Le, Jacqui Elizabeth Hoffman
  • HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
    Publication number: 20170057947
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g.
    Type: Application
    Filed: November 11, 2016
    Publication date: March 2, 2017
    Applicant: PFIZER INC.
    Inventors: MICHAEL AARON BRODNEY, JENNIFER ELIZABETH DAVOREN, AMY BETH DOUNAY, IVAN VIKTOROVICH EFREMOV, DAVID LAWRENCE FIRMAN GRAY, MICHAEL ERIC GREEN, JACLYN LOUISE HENDERSON, CHEWAH LEE, SCOT RICHARD MENTE, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, LEI ZHANG
  • Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same
    Patent number: 9579284
    Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: February 28, 2017
    Assignee: Pfizer Inc.
    Inventors: Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
  • Oral delivery product
    Patent number: D782646
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: March 28, 2017
    Assignee: Pfizer Inc.
    Inventor: Michael A. Goode
  • Oral delivery product
    Patent number: D783799
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: April 11, 2017
    Assignee: Pfizer Inc.
    Inventor: Michael A. Goode
  • Oral delivery product
    Patent number: D783800
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: April 11, 2017
    Assignee: Pfizer Inc.
    Inventor: Michael A. Goode
  • Oral delivery product
    Patent number: D783801
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: April 11, 2017
    Assignee: Pfizer Inc.
    Inventor: Michael A. Goode